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836 VAN BOVEN ETALAdherence to medication comprises a multiphased temporal
process involving (1) initiation of prescribed therapy, (2)
implementation as prescribed, and (3) subsequent persistence.
Medication adherence remains suboptimal in most patients with
long-term respiratory conditions such as asthma and chronic
obstructive pulmonary disease (COPD). Interventions have been
shown to effectively improve treatment initiation,
implementation, and persistence when delivered at the health
care professional level or the system level, but demonstration of
the cost-effectiveness of these interventions is necessary to ensure
their widespread use. This review summarizes how health care
professionals can intervene to improve medication adherence in
patients with asthma and COPD, provides some examples of
effective primary care interventions, and illustrates some of the
challenges to optimal implementation arising from cost-
effectiveness modeling. Improving adherence is shown to be an
economically viable treatment option for patients with asthma
and COPD, but there are differences in the health economics
pertaining to each condition and setting that can affect whether
an intervention is considered cost-effective. Targeting adherence
interventions at patients with the greatest to gain, and tailoring
them to individual patient needs, may help to optimize cost-
effectiveness ratios and improve the probability of positive
reimbursement decisions, systemwide implementation, and
resultant health beneﬁts.  2016 The Authors. Published by
Elsevier Inc. on behalf of the American Academy of Allergy,
Asthma & Immunology. This is an open access article under the
CC BY-NC-ND license (http://creativecommons.org/licenses/by-
nc-nd/4.0/). (J Allergy Clin Immunol Pract 2016;4:835-46)
Key words: Asthma; COPD; Medication adherence interventions;
Initiation; Implementation; Persistence; Health care
professionals; cost-effectiveness
Adherence to asthma and chronic obstructive pulmonary
disease (COPD) medication is central to achieving the desired
treatment outcomes, but epidemiological studies suggest adher-
ence remains suboptimal in most patients.1 Adherence—a term
that comprises (1) initiation of prescribed therapy; (2) imple-
mentation of therapy as prescribed (correct dose, inhalation
technique, and frequency); and (3) persistence (obtaining reﬁlls
to maintain adherence over time)—can be affected by many
factors,2 including patient and societal determinants.3 Numerous
studies have assessed the role of the patient (eg, their health
beliefs, proﬁciency, and comorbidities)4,5 and speciﬁc treatment
aspects (eg, dosing regimen, inhaler type, and adverse effects)6-9
with respect to adherence to asthma and COPD medications; far
fewer have explored the effect of system-level determinants, such
as the relationship between adherence and clinician-patient in-
teractions or the organizational structure of health care (eg,
consultation time or co-payment).
System-level determinants may, at least in part, result in
limited uptake of medication adherence interventions in routine
care. In many countries a key requirement for applying ofReceived for publication February 9, 2016; revised March 18, 2016; accepted for
publication March 23, 2016.
Corresponding author: JobF.M.vanBoven,PharmD,PhD,Department ofPrimaryCare,
University ofGroningen, UniversityMedical Center Groningen, GroningenResearch
Institute for Asthma and COPD (GRIAC), Antonius Deusinglaan 1 (Rm 3217-423),
9713 AV Groningen, The Netherlands. E-mail: j.f.m.van.boven@rug.nl.medical interventions is reimbursement, which often necessitates
demonstration of the cost-effectiveness of the intervention10 and
a supporting health care policy. Interventions must be complex
enough to be effective, but simple enough to allow them to be
scaled up and adopted in routine care. A cost-effectiveness
analysis provides insight into the trade-off between ﬁnancial
investment in health care interventions and the degree of health
improvement offered. A structured assessment can inform poli-
cymakers of the value of interventions before their broad uptake.
The role of health care practitioners is one of the main
adherence determinant “domains” identiﬁed by the ASTRO-
LAB Group (see article “Mapping the asthma care process:
implications for research and practice” in this issue11). In this
article, we discuss roles and actions that different health care
providers can take to support medication adherence. We review a
number of clinician-delivered interventions that may improve
adherence to asthma and COPD medications. We also discuss
system-level cost considerations and health economic assessment
of adherence interventions for both conditions and consider how
these may affect their uptake in routine care.
THE ROLE OF PRIMARY HEALTH CARE
PROFESSIONALS IN OPTIMIZING ADHERENCE
Because most patients with asthma and COPD are managed
in primary care, interventions that general practitioners, nurses,
or pharmacists can implement within routine care have the
opportunity to reach the greatest number of patients with res-
piratory conditions.
Structured assessment in consultations
In asthma, use of structured frameworks such as the SIMPLES
(Smoking status, Inhaler technique, Monitoring, Pharmaco-
therapy, Lifestyle, Education, Support) approach can help to
identify self-management problems and empower patients
through standardized holistic assessment, avoid unnecessary
medication escalations, and guide referrals to specialist care.12
Standardizedholistic assessment suggests a dynamic consultation,
facilitating dialogue between the clinician and the patient, exploring
all aspects of the impact of asthma on the individual and vice versa,
and ending with shared decision making concerning management.
A number of components of the SIMPLES approach are relevant to
supporting medication adherence—at each step of the adherence
pathway. For example, correct Inhaler technique is integral to the
successful delivery of respiratory medications13 and a key cause of
unintentional poor medication implementation. Technique varies
substantially between devices, with most patients (and their clini-
cians) unable to consistently demonstrate correct inhaler use.14,15
Clinicians should have knowledge of a range of devices so that
they can tailor the device choice to the needs and characteristics of
the patient, minimize use of different device types (to facilitatemore
accurate therapy delivery),13,16 and teach, assess, and, where
necessary, rectify inhaler technique each time the patient is reviewed.
Monitoring of symptoms and lung function by the patients can
improve their ability to identify a deterioration in their level of2213-2198
 2016 The Authors. Published by Elsevier Inc. on behalf of the American Academy
of Allergy, Asthma & Immunology. This is an open access article under the CC
BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
http://dx.doi.org/10.1016/j.jaip.2016.03.007
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COPD- chronic obstructive pulmonary disease
FACI- facilitated asthma communication intervention
ICS- inhaled corticosteroids
RCT- randomized controlled trialSIMPLES- Smoking status, Inhaler technique, Monitoring,
Pharmacotherapy, Lifestyle, Education, Supportcontrol, prompt remedial actions (eg, trigger avoidance), and
may also help patients link poor adherence to poor control, thus
minimizing unnecessary medication escalation cost and potential
treatment adverse effects.
Regular review of Pharmacotherapy and medication use in a
systematic fashion can improve health outcomes.17 Consultations
should include a standardized assessment of patients’ execution of
each step in the adherence pathway, that is, conﬁrmation of
initiation, subsequent implementation as prescribed, and medi-
cation continuation. A patient-centered approach (which can be
deﬁned as “care that is holistic, empowering [which] tailors support
according to the individual’s priorities and needs”18) is highly
relevant for assessing and supporting medication adherence.
Where any aspect of adherence is considered to be suboptimal, an
open, nonjudgmental exploration of the possible reasons for this
should be conducted in partnership with the patient to elicit and
work with patients’ opinions, concerns, and expectations that
impair adherence.19 It is important to tailor medication dose to the
speciﬁc needs and medication attitudes of the patient with clear
instructions for upward/downward titration.
Adherence cannot be achieved by an unprepared patient.
Education on how the disease and treatment(s) work and how
and why to use medication is crucial to adherence. Consultation
time is often perceived as a barrier to successful patient educa-
tion, but recent research suggests this need not be the case.20
Although originally developed for use in asthma, the SIM-
PLES consultation model can also be adapted for use in COPD
management. With respect to adherence, in COPD, Pharmaco-
therapy is somewhat more complex than in asthma. Although
bronchodilation is the backbone of all treatment regimens,21
there has been a historical trend to use high-dose inhaled corti-
costeroids (ICS) within COPD. High doses may impact medi-
cation implementation and persistence because they can increase
the risk of unintended effects such as pneumonia or diabetes.22,23
Similarly, persistence may be reduced by COPD patients’ poor
perception of the effectiveness of ICS treatment.24
Concordance and shared treatment goals
The term “concordance” refers to the extent to which physicians
and patients share a common perception, for example, of symp-
toms or clinical problems.25 A shared understanding allows clinical
management decisions to be more successful; treatment regimens
tailored to individual patient’s needs and preferences enhance good
disease control.26 For patients, concordance can increase their
engagement and subsequent implementation of their prescribed
treatment regimen. For physicians, concordance can help with
disease monitoring, identiﬁcation of nonadherence, and reduction
of undertreatment/overtreatment. At present concordance appears
suboptimal; for example, studies report poor concordance between
patients’ and physicians’ perceptions of, and impact of, common
COPD symptoms,27 and between physicians and caregivers’understanding of prescribed maintenance therapy regimens in
children with asthma.28
Effective health care professional communication
Even where there is an established physician-patient relation-
ship, patients can be reluctant to ask for additional information or
to discuss nonrespiratory issues to avoid “wasting” the clinician’s
time.29 Yet such issues (eg, lifestyle concerns, medication attitudes,
and beliefs) can strongly inﬂuence patients’ disease management.30
Thus, it is important for clinicians to use empathy and relevant
communication approaches (eg, open questions and attentive
listening) to build trust and support full and honest discussions.
There is a large body of research on effective communication
techniques for clinical consultations.31,32 A systematic review has
identiﬁed a number of verbal and nonverbal physician behaviors
that appear to be associated with better interpersonal relationships
with patients, improved patient understanding of health care
advice, and their subsequent medication implementation (see
Table I).33 At the end of a consultation, inviting patients to repeat
(“tell-back”) the information that has been shared with them
provides an opportunity to appraise patient comprehension and a
means to correct, clarify, and reinforce key messages. Patients have
been shown to prefer the use of the Tell-Back-Collaborative
approach where patients are asked, in a patient-centered manner,
to restate what they understand in their ownwords; for example, “I
can hear you’re worried about [this treatment]. I’ve given you a lot
of information; it would be helpful for me to hear your under-
standing about [this treatment].” This approach contrasts with
alternative strategies, such as Yes-No evaluations (eg, “I’ve given
you a lot of information. Do you understand?”), or Tell-Back-
eDirective approaches (eg, “It’s really important that you do this
exactly the way I explained. What do you understand?”).34
Engaging with medication beliefs of patients
Given that noninitiation, suboptimal implementation, and
poor persistence/early discontinuation of asthma and COPD
medication is common, guidelines understandably encourage
general practitioners to address medication adherence with their
patients at regular intervals.35 Yet many physicians are unsure
about how to carry out effective adherence counseling36 and
uncertain of how to ask patients about adherence behaviors
sensitively, so as to obtain reliable answers. Indeed, the speciﬁc
wording used to ask patients about their medication use can be
key to ensuring accurate patient reports. In 85 adult patients
with asthma, the 3 questions detailed in Table II were strongly
associated with actual adherence (measured by electronic moni-
toring), but the commonly used Morisky self-report question-
naire was only moderately associated with actual adherence.37
Patient-centered approaches to supporting
adherence
Once poor adherence has been identiﬁed, the next logical step is
to provide the patient with effective adherence support. Patient-
centered techniques, such as motivational interviewing, can help
clinicians to elicit patients’ views, beliefs, and concerns about their
disease and its treatment, or other medical matters. Understanding
patients’ attitudes, beliefs, and concerns can help physicians to work
with the patient to develop feasible health action plans centered on
patients’ personal goals. A set of simple, evidence-based support
tools, drawing on motivational interviewing principles, has been
developed to guide primary care clinicians in providing patient-
centered adherence (implementation and persistence) counseling
TABLE I. Physician behaviors associated with positive and negative patient outcomes in primary care37
Communication behaviors associated with positive patient
outcomes Communication behaviors associated with negative patient outcomes
Friendliness and courtesy Formal, antagonistic, directive, or dominant physician behavior
Attentive listening High rates of biomedical questioning
Empathy (expression of appreciation of a patient’s situation) Interruptions by physician
Statements of reassurance and support Physician irritation or nervousness
Patient-centered strategies (eg, encourage patient’s
questions/allow patient’s point of view to guide end of
visit)
Tension
Positive reinforcement (expression of encouragement
concerning patient’s actions/self)
One-way information ﬂow from patient to provider
Humor (relief of tension) Expression of opinion during physical examination
Psychosocial talk (ie, asking about problems of daily living,
social relations, feelings, and emotions of patient)
Counseling for psychosocial issues
Explanation
Orienting the patient during physical examination
Summarizing
Health education and information sharing (eg, discussion of
treatment effects or sharing medical data)
Talking at the patient’s level/using clarifying statements
Nonverbal communication behaviors associated with positive patient outcomes
Head nodding
Forward lean
More direct body orientation (ie, physician’s body facing rather than turning away from patient)
Uncrossed legs and arms
Symmetrical position of the arms (eg, both arms hanging straight down)
Less mutual gaze
TABLE II. Phrases to identify patients’ self-reported medication
adherence
Lots of people don’t take their inhaler exactly as prescribed. In the last 4
weeks:
1. How many days per week have you been taking your [name of
controller] inhaler?
2. How many times per day?
3. How many puffs do you take each time?
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838 VAN BOVEN ETAL(Figure 1).38Applicationof these approaches in routine primary care
was shown to increase clinicians’ conﬁdence in counseling patients
with asthma on adherence with preventer therapy; it also increased
the frequency with which counseling was provided. Goal-setting
record cards can be provided as a written reminder of patients’
personal goals and chosen action strategies.39 An evidence-based
model of the clinician-patient partnership has been developed for
asthma that has the concept of effective communication, collabo-
ration, and personalized goal setting as a means to help reduce pri-
mary care and emergency department visits (Figure 2).40
Tailoring consultation style toward patient
preferences and shared decision making
Clinicians should aim to tailor their consultation style to the
preferences, health literacy, and cognitive ability of each indi-
vidual patient. A straightforward, but effective, way of opening a
dialogue about patients’ preferences is to request their feedback
on their consultation.41 Because poor health literacy is common
and can often go undetected, it is good practice to ask patients to
verbalize their understanding of any new concepts, using the
aforementioned Tell-Back collaborative approach, to check
comprehension, and to identify and correct potential mis-
understandings.42 Shared decision making can be deﬁned as an
active mutual partnership between the health care provider and
the patient in which both parties share information, values,
preferences, and decisions about treatment.43,44 Shared decision
making has been effective and cost-effective in patients with
asthma,45 but the approach may be preferred in younger, more
educated individuals and in those with poorer adherence.46Thus, involvement in treatment decision making may not be
appropriate to all and should be targeted appropriately toward
those who are willing and able to participate.46
In consultations with children and their parents, it is important
to elicit the child’s perspective (asking, listening, acknowledgment
of the child’s opinion) as early as developmentally possible. Chil-
dren 7 years or older are generally considered reliable reporters of
their asthma symptoms and health status.47,48 Patient-centered
care and shared decision making can be successfully included in
pediatric asthmamanagement; for instance, the health professional
can form a partnership with the parent that allows them both to
share information and decision making with the child, appropriate
to the child’s developmental level.49 Joint discussions with the
child and the child’ caregiver about respective responsibilities (eg,
for medication administration, remembering to take it, and
obtaining reﬁlls) are very important, particularly as adolescence
approaches, because early engagement in asthmamanagement will
help prepare children for their inevitable responsibility in later
adolescence and adulthood life.
FIGURE 1. Example of adherence counseling support tools. These adherence counseling support tools are designed to facilitate a flexible,
personalized adherence discussion between a health professional and patient in a single, brief consultation. Patient’s personal barriers to
adherencewith asthma preventer treatment (such as “Preventer concerns” or “Doubting chronicity”) can be identified through the use of a
brief, evidence-based asthma attitude questionnaire (see Foster et al38) and/or an empathic conversation that is accepting of non-
adherence. The resource sheets shown in Figure 2 describe common reasons for poor adherence and common misconceptions. The
general practitioner ticks off relevant topics to personalize the resource sheet, and provides it to the patient so they can discuss together
the extent to which the information is relevant from the patient’s perspective. For example, patients concerned about adverse effects of
treatment may overlook the adverse effects of poor medication implementation or persistence, for example, being unable to do the things
they want to in life due to asthma symptoms or exacerbations. According to the principles of motivational interviewing, encouraging the
ambivalent patient to talk about the benefits (as well as the down sides) of treatment can help them decide to adhere to prescribed
treatment. From Foster et al,38 reprinted with permission.GP, General practitioner;MICA, Management to Improve the Control of Asthma.
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FIGURE 2. Model of clinician-patient partnership in asthma.40 From Clark et al,40 reprinted with permission from SAGE Publications, Inc.
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840 VAN BOVEN ETALRole of the community pharmacist
Primary care physicians offer a well-trained and familiar
resource from which patients can seek guidance about their
condition and treatment. Yet primary care resources are under
pressure owing to ever-increasing demand and respiratory care
remains suboptimal.50 In such resource-limited scenarios (and
more generally), community pharmacies can complement and
reinforce existing primary careeled support services to improve all
aspects of medication adherence and decrease hospitalizations.51
The accessibility of community pharmacies is a key to the role
they can play in supporting primary care services. In the United
Kingdom alone, 438 million visits are made to community
pharmacies each year for health caree related reasons—more
visits than are made to any other health care setting in the
country.52 Community pharmacies offer patients a unique set of
service features, which positions them well to support patient
care.53 These features include their speciﬁc training on optimal
selection and use of pharmacotherapy, geographical distribution
(including in deprived areas), position as a trusted health care
professional,54 and ﬂexible opening hours (particularly eveningsand weekends). Furthermore, for those patients who use a regular
pharmacy, there is opportunity to build patient-pharmacist
rapport, to support patients, and capture longitudinal medica-
tion adherence data to identify potential noninitiation, subop-
timal implementation, and potential discontinuation.
Although there are inherent limitations to providing support
at the point of dispensing (eg, lack of privacy) and in the context
of potential commercial operational drivers, the role of the
pharmacist is important across all steps in the medication
adherence pathway, in setting expectations around treatment use
at the time of initiation, providing device training to support
medication implementation, and in terms of medication usage
reviews to assess persistence and identify discontinuation.55
Specific pharmacy tools
Pharmacies usually save each patient’s drug history to a unique
patient medication record, which, along with their dispensing
history, pharmacists can use to identify patients in need of potential
support56; for example, a patient with asthma who is overusing his
or her reliever inhaler(s) and/or underusing his or her preventer
TABLE III. Expected clinical and economic effects of adherence-enhancing interventions for maintenance treatment in patients with
asthma and COPD
Focus of intervention
Intensity of use (eg, reminders, motivational
interviewing, and education) Quality of use (eg, inhalation technique)
Costs
Intervention costs [ [
Medication costs [ (maintenance),
Y (reliever)
z (maintenance),
Y (reliever)
Other health care costs (eg, hospitalizations) Y Y
Effects
Beneﬁcial pulmonary effects [ [
Local adverse effects [ (maintenance),
Y (reliever)
Y(maintenance)
Y (reliever)
Systemic adverse effects [ [
Beneﬁcial extrapulmonary effects [ (mainly in multimorbidity) z
Y, Decrease; [, increase; z, similar.
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patient services, such as the Medicines Use Reviews and the New
Medicine Service, have been developed in the United Kingdom for
adoption by community pharmacies.58 These services offer phar-
macists ﬁnancial incentives to provide patients with additional
care. For those patients who do not attend primary care, pharmacy
Medicines Use Reviews could be beneﬁcial in tailoring treatment
and optimizing all aspects of medication adherence. Existing
dispensing software allows for brief, cost-effective, and tailored
interventions.55,58 Simple advice, such as advising patients about
common adverse effects, and how to manage them, can have a
signiﬁcant impact on medication adherence.58
As frequently visited health care “hubs,” community phar-
macies have the potential to monitor adherence, to intervene as
appropriate, and to capture valuable reﬁll data for use in
adherence research. Their role in optimizing medication adher-
ence (eg, “timely” initiation assessments and extent to which
physician-issued prescriptions are collected by patients) and
patient care can be greatly enhanced through good communi-
cation and coworking with primary care physicians59 and by
combining physician-prescribing data with pharmacy reﬁll data
to inform more robust assessments.
PRIMARY CAREeBASED ADHERENCE
INTERVENTIONS IN ASTHMA AND COPD
Now we describe some examples of adherence interventions
suitable for primary care or community settings.
Clinician communication skills
A randomized controlled trial (RCT) in the United States
trained primary care physicians on asthma guidelines, commu-
nication techniques, and key educational skills for use in pedi-
atric consultations. Use of these skills was associated with a
signiﬁcant improvement in patient-reported physician commu-
nication skills and improved patient health outcomes (days
limited by asthma symptoms and number of annual emergency
department visits) compared with the control group.60
Patient communication skills
In an observational study, Butz et al61 provided communi-
cation training and support tools for use in home visits by nurse/
health educators to school-aged children with asthma and theirparents to improve children’s communication during nonurgent
primary care visits. Although no preintervention baseline data or
control group was included in the study (limiting the interpre-
tation of the results), children were observed to participate
actively in the consultation after training, with 83% personally
reporting their asthma symptoms and 75% talking about their
personal goal for asthma after prompting from a parent/nurse.
The effect of facilitated asthma communication intervention
(FACI) was also evaluated in an RCT involving more than 300
low-income preschool children in the United States.62 FACI and
FACI delivered via a mobile medical clinic (Breathmobile) were
compared with standard asthma care. Both FACI interventions
were designed to remove common barriers to asthma care: the
Breathmobile by overcoming structural barriers (transportation,
access to care, and health insurance status) and FACI by
empowering families to communicate with their physicians more
effectively. Although neither FACI intervention strategy resulted
in a statistically signiﬁcant improvement in asthma management
or asthma morbidity at 12 months (compared with usual care),
children in the Breathmobile þ FACI group had a 6.6% increase
in symptom-free days at 6 months. These ﬁndings suggest that
more research is needed to evaluate community interventions
that may result in meaningful and sustainable clinical outcomes.
Adherence counseling
In a large Belgium-based RCT (n ¼ 734), provision of
extensive counseling to patients with COPD on inhalation
technique and adherence at the point of dispensation and at
1-month follow-up resulted in statistically signiﬁcantly higher
inhalation scores and implementation measured by the propor-
tion of days covered and lower hospitalization rates after 3
months (compared with the control group).51 Positive results
were conﬁrmed in a similar, but smaller, 1-year RCT (n ¼ 146)
performed in Spanish primary care patients with COPD.63
Adherence information feedback
The potential value of routine monitoring of asthma medi-
cation adherence, with feedback of this information to patients,
for sustaining high levels of adherence has been assessed in a few
small studies64,65 and, more recently, in a large-scale practice-
RCT.66 Implementation of ICS therapy was estimated using
combined prescription and reﬁll data in patients with asthma
FIGURE 3. Potential clinical and/or economic benefits of targeting adherence interventions toward subgroups of patients with chronic
respiratory diseasewith considerable room for improvement. As the diagram shows, benefits of adherence interventions are more likely to
be observed if interventions are targeted at specific groups such as those working, taking multiple medications, experiencing exacer-
bations, or having uncontrolled disease.
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842 VAN BOVEN ETALaged 5 to 56 years. Clinicians in the intervention arm (compared
with usual care) could view updated ICS adherence information
on their patients via electronic prescription software. After 3
months, there were no signiﬁcant differences in ICS adherence
(implementation) among patients in the intervention arm and
the control arm (P ¼ .553). However, implementation rates were
signiﬁcantly higher among those patients in the intervention arm
whose clinician elected to view their detailed adherence infor-
mation compared with the control arm patients (P ¼ .026) and
compared with those in the intervention arm whose provider did
not opt to view the detailed data (P ¼ .002). The authors
concluded that provision of adherence information to clinicians
does not improve ICS use among patients with asthma, but that
having a clinician who is sufﬁciently interested to access and view
detailed data on his or her patients’ medication use can support
and improve medication implementation.
Reminder-based interventions may also help to improve
adherence outcomes in primary care. A cluster RCT was
designed to assess the effect of general practitioners providing
their patients with twice-daily medication usage reminders for
missed doses via an electronic monitor afﬁxed to their preventer
(again, a measure of implementation). The monitor also pro-
vided visual feedback of last dose taken and uploaded the
patient’s medication-use data to a Web page that both patients
and their physicians could access to comonitor medication use.
Over 6 months, average daily medication implementation in the
intervention group was 27% higher than in the control group
(73% vs 46%). Exacerbation rates were also lower in theintervention group compared with the usual care controls (1
exacerbations, 11% vs 28%).67 Similarly, COPD RCTs68,69
report signiﬁcantly higher adherence in active versus control
groups (eg, adherent days, 60% vs 40%) who received electronic
monitoring of ipratropium bromide plus feedback.68
ROLE OF THE HEALTH CARE SYSTEM IN
OPTIMIZING MEDICATION ADHERENCE
There are few studies investigating the impact of system’s orga-
nizationon adherence, particularly in respiratory disease, but the few
studies that do exist indicate that the organization and structure of
clinics and surgeries can affect adherence to asthma treatment.
Organizational factors associated with improved adherence include
fewer patients seen per hour, longer appointment length, evening
consultation hours, multilingual staff, consistency of care, ease of
making appointments, ease and effectiveness of telephone
communication, anduse of telephone calls for reminders and follow-
up.70 In contrast, increasing co-payments for visits and medication
were associated with poorer adherence (where adherence was a
generalized term in a systematic review involving 160 articles and
encompassed reported adherence, compliance, noncompliance, and
persistence).71 More research is needed to understand how health
care systems can be improved to better support medication adher-
ence in asthma and COPD.
COST-EFFECTIVENESS
The ﬁrst prerequisite for adherence interventions to be
cost-effective is a proper asthma or COPD diagnosis, along
TABLE IV. The International Primary Care Respiratory Group’s
adherence-related research priorities for asthma and COPD96
Research category Research need
Asthma
Compliance What is the impact of patients’ comprehension of
the disease, use of different treatment
strategies, treatment cost (in high- and
low-income countries and between social
groups), and concern about adverse effects of
inhaled steroids on adherence to prescribed
treatment
Compliance How may these issues of adherence be addressed
(especially in subgroups such as the adolescent
patient with asthma)?
COPD
Self-management What is the optimal format of self-management
education (including the information content,
individualization of the plan, written or
electronic delivery, professional or lay
educators) to ensure effective communication
with patients (often from deprived
communities), facilitation of adherence to
treatment, and a positive impact on health
status?
TABLE V. Proposed adherence research needs within the health
care system and health economic domains
Health care systems (including health care professionals)
 Design and uptake of integrated system-level (multilevel)
interventions that work across multidisciplinary teams:
B Simple global models that can be tailored to local settings
 Development of a framework and models to underpin
defragmentation and integration of data across different health care
assets (eg, integration of pharmacy data, primary and secondary care
data, and patient-reported outcomes)
 Validation of adherence proﬁles deﬁned through electronic medical
record (eg, pharmacy and prescribing reﬁll data)-based research
 Development of methods and models to improve the engagement
of health care professionals (and providers) in the promotion of medi-
cation adherence to their patients (and clients)
 Assessment (and provision) of appropriate knowledge, skills, and
attitudes within the health care system to facilitate optimal adherence
 Evaluation of the effect of medication changes on treatment
adherence and future risk
 Development of core variables that E- and M-Health applications
should collect to ensure the availability of valuable data for future
adherence research
 Evaluation of the potential for artiﬁcial intelligence and machine
learning to inform and guide adaptive care delivery to optimize
adherence and clinical outcomes
 Evaluation of the cost-effectiveness and scalability of
adherence interventions (to aid in their promotion and successful
uptake)
Health economics and scalability
 Development of standardized health economic measures for use
in cost-effectiveness modeling of respiratory adherence interventions
 Improved reporting of the methods used in health economic modeling
of respiratory adherence research
 Multifactorial analysis approaches for the evaluation
of cost-effectiveness of adherence interventions
 Evaluation of the real-world (cost)-effectiveness of licensed respiratory
therapies
 Development of research methods to identify target populations in
whom adherence interventions will be most cost-effective
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pharmacological treatment. Second, better use of existing respi-
ratory therapies may be more cost-effective than investing in new
technologies.72 However, the extent of cost-effectiveness of any
given intervention is largely dependent on the macroeconomic
burden of the disease it is intended to treat and is likely to vary
depending on the condition, country, and context in which ther-
apy is used. For example, an intervention may appear feasible for
both asthma andCOPD, butmay be cost-effective only when used
in patients with COPD or in an asthma subpopulation.73
Cost-effectiveness of adherence management in
COPD
Before assessing the cost-effectiveness of adherence in-
terventions in patients with COPD, it is important to ﬁrst
establish the overall economic burden of COPD to identify the
potential economic gain of different management approaches.
For example, in the Netherlands, evaluation of the macroeco-
nomic burden of COPD reveals that approximately 35% of the
total national costs of COPD are incurred as medication costs74
whereas the other 65% are mainly incurred through hospitali-
zations and health care consultations. In other countries, cost
patterns may be very different. Notably, nonadherence (non-
initiation, poor implementation, and early discontinuation) in
COPD is associated with worsened clinical and economic out-
comes, speciﬁcally higher rates of hospitalizations and exacerba-
tions and greater mortality and work productivity losses.75-77
Interventions targeted at improving medication adherence (any
or all steps of the pathway) may be able to improve clinical
outcomes and reduce associated costs. The initial cost of the
adherence intervention (and its associated medication) may be
offset by the intervention’s ability to reduce rates of costly events
(eg, hospitalizations).78 Studies that assess the cost-effectiveness
of adherence interventions in COPD are scarce, but those that
exist do suggest favorable cost-effectiveness.78,79Cost-effectiveness of adherence management in
asthma
Similar to COPD, suboptimal adherence to asthma medication
has been shown to be associated with poor clinical and economic
outcomes.80 Yet, in many countries, the macroeconomic burden
of asthma differs considerably from that of COPD. In the
Netherlands, medication costs account for 65% of the total na-
tional asthma expenses (in contrast to 35% in COPD) and this
high proportion of medication costs limits the extent to which
adherence interventions can reduce the total national expense for
asthma.74 Hospitalization is a large expense, but, at least in
countries with well-developed asthma care, baseline hospitalization
rates in asthma are low (4%), leaving little opportunity to
decrease total asthma costs signiﬁcantly through better adherence
(and resultant improved clinical outcomes) alone.81 Decreased
national costs for asthma could therefore be achieved only by
better adherence and decreased unit cost of medication. Therefore,
although improvement in Global-Initiative-for-Asthmaedeﬁned
symptom control has been shown to reduce direct asthma-related
health care costs,82 the cost-effectiveness of increasing medication
intensity is equivocal.83 In countries where asthma care is less
developed or in countries with limited health insurance or social
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can be relatively much higher.84 Consequently, asthma adherence
interventions have greater potential to be cost-effective in those
countries.73,84 Interventions targeted at improving inhalation
technique, however, may offer greater cost-effectiveness in coun-
tries with high medication costs as a proportion of asthma total
cost. Improved inhalation technique promotes more effective
outcomes from an existing medication, which can reduce costs
through, for example, lower prescribing of add-on medications or
high strength inhaled steroid therapy (Table III). Unfortunately,
we could not ﬁnd any published, well-performed cost-effectiveness
studies on this speciﬁc topic.
Targeting of interventions
To maximize outcomes and cost-effectiveness, the appropriate
targeting of interventions should be considered. Targeting aims to
identify subgroups of patients who stand to beneﬁt most from a
speciﬁc intervention, in either clinical and/or economic terms, and
to prioritize use appropriately. Adherence interventions should be
effective for the appropriate step of the adherence pathway (initi-
ation, implementation, or persistence) and applied only in patients
with suboptimal adherence behaviors as identiﬁed a priori. From a
principally cost-effectiveness perspective, further targeting of the
use of interventions may be guided by the intervention’s ability to
reduce high-cost health care resource utilization (eg, severe exac-
erbations) and/or tominimize the socioeconomic impact of disease
(eg, in working age patients) (Figure 3).
Identifying patients with poor adherence and/or at
high risk of exacerbation. As previously mentioned, phar-
macy reﬁlls (or prescription renewals in the clinic) could be used to
identify nonadherent, potentially at-risk patients with COPD85 or
asthma,57 helping to target interventions at those with the greatest
to gain from the intervention. Validated patient questionnaires
such as the Asthma Control Test or the Asthma Control Ques-
tionnaire could be used to identify and target patients with un-
controlled disease because, especially in those with uncontrolled
asthma (Asthma Control Test score<20), fewer exacerbations are
associated with higher rates of medication adherence.86
Targeting patients with comorbidities and poly-
pharmacy. Patients with COPD tend to suffer from multiple
comorbidities and are dependent on use of polypharmacy.
Research indicates that interventions focusing on adherence to
COPD medication may also result in beneﬁcial extrapulmonary
effects in patients with COPD, possibly due to more healthy
patient behavior (eg, lifestyle changes and better adherence to
comedication).78 Indeed, counseling and education on the ben-
eﬁts of adherence to one prescribed therapy results in improved
adherence to comedication.87
Targeting patients of working age. Although direct
health care costs are usually somewhat lower in the working age
asthma population, indirect costs (such as lost productivity)
contribute substantially to the overall societal burden of chronic
conditions such as asthma.88 Model-based approaches often
suggest equivocal cost-effectiveness of adherence interventions in
asthma, but when reduction in lost productivity is included they
can offer economic beneﬁt.83 Also, in COPD, indirect costs (lost
and impaired productivity) exceed direct medical costs in the
working age population, indicating the potential for cost-
effectiveness of adherence interventions.89Targeting interventions to high-risk periods. In
COPD, exacerbations are up to 4 times more frequent in winter
than in summer months90,91 whereas in infants and school-aged
children with asthma, severe exacerbations are more frequent in
winter or at return to school, respectively. Using interventions
before/during critical seasonal periods may result in a more
concentrated effort, a greater reduction in exacerbation frequency,
and better relative gains and increased cost-effectiveness,92
although clinically and behaviorally it may be preferential for pa-
tients to establish a consistent daily medication-taking routine.
Target, but do not forget to tailor
Beyond targeting, it remains essential that interventions are
selected and tailored to the individual needs of the patient. For
example, patients who fail to initiate, implement, and/or persist
with therapy because of speciﬁc beliefs about treatment (eg, adverse
effect concerns) are unlikely to beneﬁt from treatment reminders.
Therefore, identifying adherence patterns and investigating the
reasons for these patterns remain essential. Emerging technologies
such as “Smart Inhalers” can provide real-time insight into pa-
tients’ unique medication-use pattern including evidence of sub-
optimal inhalation technique.93-95 Systematic approaches for the
recording of patients’ unique medication adherence barriers and
communication techniques to address these are also emerging in
the adherence literature.37,38 Ongoing and future research into the
potential role of such technologies will help inform and guide their
optimum use. Last, some adherence interventions (eg, automated
texting programs and sending letters to patients who do not reﬁll
their medications) can be very low cost, whereas others (eg, case
managers who reach out to patients with recent exacerbations) are
usually more costly. Tailoring therefore may include directing
more cost-intensive programs for those patients who have been
hospitalized for their asthma or COPD.
CONCLUSIONS
Health care professionals—clinicians, nurses, and pharma-
cists—have a key role to play in engaging and educating respi-
ratory patients on the potential beneﬁts of treatment, monitoring
adherence, and in providing ongoing education and inhaler
technique training. Health care professionals should be conscious
of the range of factors that can facilitate (or inhibit) medication
initiation, implementation, and persistence (ie, adherence), such
as use of appropriate consultation skills, language, collaborative
goal setting, and continuity of care.
From a health care cost perspective, improving adherence (all
steps) can be economically viable for patients with asthma and
COPD, but cost-effectiveness estimates differ substantially
between these conditions, between countries, and also across
subpopulations. Moreover, targeting adherence interventions at
patients with the greatest to gain from available interventions
may help to improve cost-effectiveness.
Looking forward, research efﬁciencies can be achieved through
identifying and addressing priority adherence-related research
needs such as those published by the International Primary Care
Respiratory Group (Table IV).96 The central role that the rela-
tionship between patients and their health care professionals can
play in achieving more tailored and individualized care has been
emphasized in this review, but more work is required to quantify
the beneﬁt of some of these approaches, such as SIMPLES.
Therefore, additional research needs are proposed in Table V—a
reﬂection on some of the system-level, cost-effectiveness, and
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expected to further improve medication adherence and quality of
life of patients with asthma and COPD in a cost-effective manner.Acknowledgment
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